Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Ab™
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
HomeMouseAtlas
C57BL/6JCya-Elf1em1flox/Cya
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Catalog Type
Product Name
Main Area of Research
How did you hear about us?
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.

C57BL/6JCya-Elf1em1flox/Cya

Common Name
Elf1-flox
Product ID
S-CKO-02182
Backgroud
C57BL/6JCya
Strain ID
CKOCMP-13709-Elf1-B6J-VA
Status
Research and Development
When using this mouse strain in a publication, please cite “Elf1-flox Mouse (Catalog S-CKO-02182) were purchased from Cyagen.”
cKO Models
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
+
cKO Models
Basic Information
Strain Name
Elf1-flox
Strain ID
CKOCMP-13709-Elf1-B6J-VA
Gene Name
Elf1
Product ID
S-CKO-02182
Gene Alias
p70, Sts1, Elf-1, mElf-1
Background
C57BL/6JCya
Gene Full Name
E74 like ETS transcription factor 1
Modification
Conditional knockout
NCBI ID
13709 (Mouse)
Phenotype
MGI:107180
Chromosome
Chr 14 (Mouse)
Application
--
Datasheet
Click here to download >>
More
Rare Disease Data Center >>
Strain Description
Ensembl Transcript ID
ENSMUST00000040131
NCBI Transcript ID
NM_007920
Target Region
Exon 3
Size of Effective Region
~1.0 kb
Overview of Gene Research
Elf1, also known as E74-like factor 1, is a transcription factor belonging to the Ets family. It plays diverse roles in multiple biological processes. In transcription, it has been associated with transcription-coupled repair pathways [4,8]. In the context of immunity, it is involved in macrophage development [5]. It also has implications in cell proliferation, migration, and autophagy regulation, thus being linked to various disease-related pathways [2,3,6]. Genetic models such as zebrafish are valuable for studying its functions [5].

In systemic lupus erythematosus (SLE) patients, ELF1 gene expression is significantly downregulated in CD4+ T cells compared to healthy controls. Its expression is also decreased in certain SLE subgroups, and ROC curve analysis indicates its diagnostic potential for SLE, as well as its value in assessing disease activity and renal involvement [1]. In early pregnancy loss (EPL), ELF1 is lowly expressed in placental villous tissues. Overexpression of ELF1 promotes proliferation and migration of trophoblast cells, suggesting its role in EPL [2]. In glioma, high expression of ELF1 may be related to the malignant behavior of the tumor, as silencing ELF1 inhibits glioma cell growth and migration with ATF5 involvement [3]. In lung cancer cells, ELF1 suppresses autophagy to reduce cisplatin resistance via the miR-152-3p/NCAM1/ERK axis [6]. In gastric cancer, ELF1 is overexpressed and combined with MMP9, it can serve as a predictor of malignant biological behavior and a prognostic indicator, being associated with the tumor microenvironment [7].

In conclusion, Elf1 has essential functions in transcription-coupled repair, macrophage development, and processes related to cell proliferation, migration, and autophagy. Its study through model-based research has revealed its significance in diseases like SLE, EPL, glioma, lung cancer, and gastric cancer. These findings provide insights into disease mechanisms and potential therapeutic targets.

References:
1. Zhang, Yukun, Cai, Minglong, Huang, Xiaoyi, Gao, Jinping, Sheng, Yujun. 2024. ELF1 serves as a potential biomarker for the disease activity and renal involvement in systemic lupus erythematosus. In Scientific reports, 14, 26590. doi:10.1038/s41598-024-78593-y. https://pubmed.ncbi.nlm.nih.gov/39496744/
2. Zhu, Pengfei, Dou, Chengli, Song, Zhijiao, Wu, Xueqing, Miao, Yiliang. . ELF1/PRR11/ARP2/3 promoted trophoblast cells proliferation and motility in early pregnancy. In American journal of reproductive immunology (New York, N.Y. : 1989), 90, e13758. doi:10.1111/aji.13758. https://pubmed.ncbi.nlm.nih.gov/37641376/
3. Hu, Ming, Li, Huanting, Xie, Hongwei, Ma, Junwei, Che, Shusheng. 2021. ELF1 Transcription Factor Enhances the Progression of Glioma via ATF5 promoter. In ACS chemical neuroscience, 12, 1252-1261. doi:10.1021/acschemneuro.1c00070. https://pubmed.ncbi.nlm.nih.gov/33720698/
4. Selvam, Kathiresan, Xu, Jun, Wilson, Hannah E, Wang, Dong, Wyrick, John J. 2024. Elf1 promotes transcription-coupled repair in yeast by using its C-terminal domain to bind TFIIH. In Nature communications, 15, 6223. doi:10.1038/s41467-024-50539-y. https://pubmed.ncbi.nlm.nih.gov/39043658/
5. Tan, Qianli, Wang, Jing, Hao, Yimei, Pan, Weijun, Cao, Mengye. 2025. Elf1 Deficiency Impairs Macrophage Development in Zebrafish Model Organism. In International journal of molecular sciences, 26, . doi:10.3390/ijms26062537. https://pubmed.ncbi.nlm.nih.gov/40141178/
6. Zhao, Lifeng, Wu, Xiangsheng, Zhang, Zhiwen, Yang, Bo, Li, Yepeng. 2023. ELF1 suppresses autophagy to reduce cisplatin resistance via the miR-152-3p/NCAM1/ERK axis in lung cancer cells. In Cancer science, 114, 2650-2663. doi:10.1111/cas.15770. https://pubmed.ncbi.nlm.nih.gov/36846943/
7. Zhang, Xiaoxia, Ren, Xiaoyan, Zhang, Shu, Wang, Yan. 2024. Overexpression of ELF1 combined with MMP9 is associated with prognosis and tumor microenvironment in gastric cancer. In Experimental and therapeutic medicine, 28, 441. doi:10.3892/etm.2024.12730. https://pubmed.ncbi.nlm.nih.gov/39583246/
8. Sarsam, Reta D, Xu, Jun, Lahiri, Indrajit, Wang, Dong, Leschziner, Andres E. 2024. Elf1 promotes Rad26's interaction with lesion-arrested Pol II for transcription-coupled repair. In Proceedings of the National Academy of Sciences of the United States of America, 121, e2314245121. doi:10.1073/pnas.2314245121. https://pubmed.ncbi.nlm.nih.gov/38194460/
Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Inquiry Details
Main Area of Research
Service(s) of Interest
Gene of Interest
Project Details
How did you hear about us?
Contact Information
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research